Venus Medtech buys InterValve

123

Venus Medtech has purchased InterValve, which sells balloon aortic valvuloplasty products and is focused on transcatheter aortic valve treatment. A press release reports that InterValve’s two trademark products—V8 and TAV8—are the world’s pioneering aortic valvuloplasty balloon catheters with anatomical shapes.

According to the press release, the unique “8-shaped” design of the products—aiming at the lesion of aortic stenosis—can complete the percutaneous balloon angioplasty, the predilatation and the postdilatation during transcatheter aortic valve implantation (TAVI). Compared with the traditional long cylindrical balloon, InterValve’s balloons are more in line with the anatomical structure of the aortic valve and, therefore, can fully protect the valve annulus structure while maximising the expansion of the valve. This type of 8-shaped balloon is designed to bring maximum safety and valve expansion.

Eric Zi, chief executive officer of Venus Medtech, comments: “The balloon of Intervalve can accurately match the annulus and guarantee the steady expansion of the balloon, so the valve can fully expand itself without injuring the implanted valve. The fine match of the balloon with the valve’s anatomical structure, combined with the use of the self-expanding transcatheter aortic valve, will greatly decrease the incidence rate of perivalvular leakage. It will also reduce the use of rapid pacemaker and significantly lower the risk of annulus tearing.”

 

 

LEAVE A REPLY